Laverock Therapeutics uses GEiGS technology to engineer iPSC-derived cell therapies
Sep. 1, 2022
Laverock Therapeutics Ltd. (formerly Skylark Therapeutics) recently completed a seed funding round to support its development of a unique gene silencing platform for the creation of programmable, allogeneic cell therapies.